New office and laboratory at CIC Philadelphia will support US biopharma companies, CDMOs, and research institutions ...

LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, ...

Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first ...

Researchers from Nagoya University in Japan have developed a durable fuel-cell catalyst by wrapping platinum nanoparticles in nitrogen-containing graphene and placing them on carbon nanotubes. This ...

Avai Bio and Austrianova established Insulinova as an equally owned joint venture to explore encapsulated cell-based therapies for diabetes. Under the collaboration with OSR, the partners will ...

LAS VEGAS, NEVADA, Sept. 24, 2026 (GLOBE NEWSWIRE)-- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí” or the "Company”), together with joint venture partner Austrianova, today announced that Prof. Walter H.

The funded teams will progress through a four-year, multi-phase program, with their performance evaluated against stringent ...

Researchers report that Ailanthus excelsa quassinoids delivered in chitosan nanoparticles suppress STAT3-driven PD-L1 ...

Draper received up to $7.3 million other transaction award (OTA) from the Advanced Research Projects Agency for Health (ARPA-H) for Phase 1 ...

Avaí Bio, Inc. together with its joint venture partner Austrianova, announced the successful encapsulation of GMP-quality Klotho-producing cells in the joint venture?s signature technology, ...